May 29, 2026 — On May 15, 2026, the FDA approved IMMGOLIS (golimumab-sldi) and IMMGOLIS INTRI (golimumab-sldi), the first biosimilars to J&J's Simponi and Simponi Aria. Developed by Bio-Thera Solutions and commercialized by Accord BioPharma, the approvals carry interchangeable designation — enabling automatic pharmacy-level substitution.
This marks the latest chapter in the TNF-alpha inhibitor market's maturation, joining biosimilar alternatives to adalimumab, infliximab, and etanercept. For API suppliers, the approval signals expanded demand and new competitive dynamics.
Golimumab is a fully human monoclonal antibody (IgG1κ) targeting TNF-α, addressing rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and ankylosing spondylitis. Key manufacturing considerations include CHO cell culture optimization for high-titer expression, glycosylation consistency across batches, and dual presentation formats covering both subcutaneous prefilled syringes and intravenous vials.
The interchangeable designation drives faster adoption since pharmacists can dispense without physician intervention, creating higher volume requirements for raw materials. PBMs and insurers favor interchangeable biosimilars for formulary positioning, while the dual SC/IV presentations double fill-finish complexity.
The TNF-alpha class represents over $25 billion in annual biologic sales. Each new biosimilar requires reliable supply of cell culture media, chromatography resins, viral filtration membranes, and formulation excipients. With golimumab biosimilars now entering the market, aggregate demand for manufacturing inputs continues to grow.
As blockbuster biologics face biosimilar competition, aggregate demand for manufacturing inputs grows even as margins compress. Suppliers offering integrated solutions from cell line development through commercial fill-finish are best positioned. Early engagement during process validation remains key to capturing long-term volume.
